| 摘要 |
FIELD: medicine, oncology. ^ SUBSTANCE: in patient's blood one should detect the content of CD16+ lymphocytes, moreover, the content ranged 5.6-7.5%, 15.1-20% or above 30% at the level of prostate-specific antigen ranged 0-12 ng/ml specifies benign tumor, and the content of CD16+ lymphocytes ranged 0-5.5% or 7.6-15% or 20.1-30% at the level of prostate-specific antigen being above 12 ng/ml demonstrates malignant tumor, and at the level of prostate-specific antigen ranged 0-12 ng/ml the content of prostate-specific antigen should be measured twice not less at 1-mo-long interval and increased level of prostate-specific antigen shows malignant tumor. ^ EFFECT: higher efficiency and accuracy of differential diagnostics. ^ 6 ex |
